Combination Studies With The Vascular Disrupting Agent CA4P
Clinical Studies combined with chemotherapy and radioimmunotherapy, and DCE-MRI and immunohistochemistry correlation
978-3-8383-4353-2
3838343530
256
2011-05-10
79,00 €
eng
https://images.our-assets.com/cover/230x230/9783838343532.jpg
https://images.our-assets.com/fullcover/230x230/9783838343532.jpg
https://images.our-assets.com/cover/2000x/9783838343532.jpg
https://images.our-assets.com/fullcover/2000x/9783838343532.jpg
This work represents studies carried out at Mount Vernon Hospital and UCL, and sponsored by Cancer Research UK, between 2003 and 2006. Phase I/II Clinical trial studies of the vascular disrupting agent Combretastatin A4 Phosphate (CA4P) are presented - in combination with cytotoxic chemotherapy (Paclitaxel and Carboplatin), and radioimmunotherapy. Dynamic Contrast Enhanced MRI data from the studies is presented and discussed, and a supporting immunohistochemistry correlation study of vascular markers is also presented.
https://www.morebooks.shop/books/de/published_by/lap-lambert-academic-publishing/47/products
Medizin
https://www.morebooks.shop/store/de/book/combination-studies-with-the-vascular-disrupting-agent-ca4p/isbn/978-3-8383-4353-2